Immunotherapy has entered the clinical treatment for various tumors,among which the blockade therapy of PD-1/PD-L1 immune checkpoint is currently the most important tumor immunotherapy method.At present,immunohistochemical method are used in clinical practice to detect PD-L1 expression in tumor patients and screen for indications.However,this method is constrained by factors such as heterogeneity,dynamic changes in PD-L1 expression,and limited sample collection.PD-(L)1 PET imaging utilizes radiolabeled molecules to non-invasively assess PD-(L)1 expression in space and time,and complementary use with IHC has theoretically incomparable advantages.This article reviews the latest progress in the PD-(L)1 probe molecular imaging principles,clinical research and existing problems.
programmed death receptor-1/programmed death receptor-ligand 1Molecular imagingPositron emission computed tomography tracerImmunotherapy
NETL
NSTL
万方数据
